

Intermittent Vagal Blocking with an Implantable Device Reduces Maximum Tolerated Volume (MTV) During a Standardized Nutrient Drink Test in Obese Subjects

DESCRIPTION

Open-label study, single-center	12 subjects <i>n=8 subjects at follow-up</i> 1 center
13–17 month follow-up	

RESULTS & SUMMARY

- vBloc resulted in early fullness in obese subjects,
- and is sustained for at least one year after onset of therapy.

Parameters	13–17-month follow-up
Mean EWL (%) at the evaluation of satiation	19
MTV mean in ingested volume at maximum satiation, following vBloc therapy, <i>n=8, p=.05</i>	-18%

To learn more, visit [www.vBloc.com](http://www.vBloc.com)



EnteroMedics, Inc.  
2800 Patton Road  
St. Paul, MN 55113 USA

TEL: 651.634.3003  
FAX: 651.634.3212

The Maestro® Rechargeable System is indicated for use in weight reduction in patients aged 18 years through adulthood who have a Body Mass Index (BMI) of 40 to 45 kg/m<sup>2</sup>, or a BMI of 35 to 39.9 kg/m<sup>2</sup> with one or more obesity related co-morbid conditions, and have failed at least one supervised weight management program within the past five years. The device should not be implanted in patients with cirrhosis, portal hypertension, esophageal varices or a significant hiatal hernia; patients for whom magnetic resonance imaging (MRI) or diathermy is planned; patients with an implanted electrical medical device or gastrointestinal device or prosthesis.

The most common related adverse events include pain, heartburn, nausea, dysphagia, eructation, and abdominal cramping.

Carefully read the product instruction manuals for complete safety information.

vBloc and Maestro are trademarks of EnteroMedics, Inc.

© 2015 EnteroMedics, Inc. All rights reserved.